Placental growth factor – Vascular endothelial growth factor receptor 1 interaction (PlGF-VEGFR-1 interaction)

The interaction between Placental Growth Factor (PlGF) and Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1, also known as Flt-1) is a key driver of pathological angiogenesis and inflammation (Source: PubMed PMID: 11544192). PlGF is a member of the VEGF sub-family that binds with high affinity specifically to VEGFR-1, but not to VEGFR-2 (Source: UniProt P49763). This binding triggers downstream signaling pathways that promote the proliferation and migration of endothelial cells, as well as the recruitment of inflammatory cells like macrophages. Unlike VEGF-A, PlGF is not essential for normal vascular development but is highly upregulated in conditions such as cancer, ischemia, and chronic inflammation (Source: PubMed PMID: 24633278). In oncology, PlGF-VEGFR-1 signaling contributes to tumor neovascularization and the formation of a pre-metastatic niche. In ophthalmology, this interaction is a major contributor to the development of wet age-related macular degeneration and diabetic retinopathy. Therapeutic strategies often involve the use of decoy receptors, such as aflibercept, which bind and neutralize PlGF before it can interact with its native receptor (Source: NIH/NCI Drug Dictionary). Additionally, the ratio of soluble VEGFR-1 (sFlt-1) to PlGF is used clinically as a biomarker for predicting and diagnosing preeclampsia in pregnant women. Targeting this specific interaction allows for the modulation of disease-associated vessel growth while potentially minimizing the systemic side effects associated with broader VEGF inhibition.

Other names

PlGF-Flt-1 interactionPGF-VEGFR1 interactionPlacental growth factor-Fms-like tyrosine kinase 1 interaction

Competitive inhibition of ligand binding through the use of decoy receptors (traps) or neutralizing monoclonal antibodies that sequester PlGF, preventing its interaction with VEGFR-1.